Facebook
X
LinkedIn
ForwardDate & Time of Session - 9/3/25 - from 2:30 - 3:30PM
Overview: Antibody-mediated rejection (AMR) following pediatric heart transplant occurs in approximately 10% of patients and can lead to graft dysfunction and ultimately death1. Treatment options for AMR include plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab. However, incomplete response may occur with these therapies. In addition, daratumumab has been suggested for use in AMR following solid organ transplant as refractory management. It is an anti-CD38 monoclonal antibody originally approved for use in multiple myeloma that has shown potential benefit in AMR due to its plasma cell depleting effects2. Multiple case reports have shown improved outcomes when used for AMR following solid organ transplant that include improved ventricular systolic function, reduction in donor-specific antibody, and improved graft function1,4-5. However, limited data has been published on the safety and efficacy of daratumumab in the pediatric heart transplant population. This presentation will explore the mechanism, clinical data, and potential role of daratumumab in AMR following pediatric solid organ transplant.
Objectives
Upon completion of this activity, participants will be able to:
1. Define antibody-mediated rejection (AMR) following transplant.
2. Describe the mechanism of action of daratumumab.
3. Evaluate the role of daratumumab in AMR following pediatric solid organ transplant with support of key clinical data.
Target Audience
Pharmacists, physicians, nurses, fellows and residents
Speaker
Jillian Garrett, PharmD, MS
PGY2 Critical Care Pharmacy Resident
Norton Healthcare
Louisville, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).
- 1.00 IPCE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.